Aptis and Cobx Bio partner to develop DAC cancer drugs

CAR-T Digest - August 2020

27 November 2025: Aptis and Cobx Bio partner to develop DAC cancer drugs

Aptis (a Dong-A ST subsidiary) and Cobx Bio have signed a collaboration agreement to jointly develop a new class of antibody-degrader conjugates (DACs), an advancement beyond traditional ADCs
DACs replace the toxic payload used in ADCs with a targeted protein degrader (TPD), enabling precise intracellular protein removal while reducing toxicity compared to conventional cytotoxic payloads
Aptis brings its third-generation AbClick site-selective linker-conjugation platform, enabling precise attachment of degrader molecules to antibodies
Cobx Bio contributes expertise in covalent inhibitors and molecular glue degraders, supported by its chemoproteomics platform RaPIDome for target and payload discovery
The partnership aims to co-develop DAC pipelines for solid and hematologic cancers, with both companies positioning the technology as a next-generation expansion of ADC-based targeted therapies